Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.

Stanley TL, Fourman LT, Wong LP, Sadreyev R, Billingsley JM, Feldpausch MN, Zheng I, Pan CS, Boutin A, Lee H, Corey KE, Torriani M and 4 more

Show all authors

Kleiner DE, Chung RT, Hadigan CM, Grinspoon SK

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America1 Aug 2021Cited by 11 (Europe PMC)

PMID33852720PMCIDPMC8366828DOI10.1093/cid/ciab019PepBankPUB-33852720

Source link PubMedAsk about this study

Jump to 17 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

17 results from studies that gave the peptide. 17 results from people.

01HumanRandomized controlled trialEfficacy outcome
In people with HIV and NAFLD, tesamorelin decreased interconnected plasma proteins related to cytotoxic T-cell and monocyte activation versus placebo.
In plain wordsIn people with HIV and fatty liver disease, tesamorelin lowered blood markers of T-cell and monocyte activity compared with placebo.
Peptide
Tesamorelin
Outcome
DecreaseCytotoxic T-cell and monocyte activation proteins
Study
n = 61
Comparator
Placebo
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Tesamorelin, compared to placebo, decreased interconnected proteins related to cytotoxic T-cell and monocyte activation.
1 context sentence(design, population, supporting numbers)
Summary · context
92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.
Report a problemFND-3385272001
02HumanRandomized controlled trialEfficacy outcome
In people with HIV and NAFLD, tesamorelin significantly decreased 13 circulating proteins and increased none.
In plain wordsIn people with HIV and fatty liver disease, tesamorelin lowered 13 blood proteins and raised none.
Peptide
Tesamorelin
Outcome
DecreaseNumber of plasma proteins changed
Study
n = 61
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Circulating concentrations of 13 proteins were significantly decreased, and no proteins increased, by tesamorelin.
1 context sentence(design, population, supporting numbers)
Summary · context
92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.
Report a problemFND-3385272002
03HumanRandomized controlled trialEfficacy outcome
In people with HIV and NAFLD, tesamorelin decreased plasma CCL3 versus placebo.
In plain wordsIn people with HIV and fatty liver disease, tesamorelin lowered blood CCL3 compared with placebo.
Peptide
Tesamorelin
Outcome
DecreaseCCL3
Study
n = 61
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Circulating concentrations of 13 proteins were significantly decreased, and no proteins increased, by tesamorelin.
2 context sentences(design, population, supporting numbers)
Summary · context
These included 4 chemokines (CCL3, CCL4, CCL13 [MCP4], IL8 [CXCL8]), 2 cytokines (IL-10 and CSF-1), and 4 T-cell associated molecules (CD8A, CRTAM, GZMA, ADGRG1), as well as ARG1, Gal-9, and HGF.
Summary · context
92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.
Report a problemFND-3385272003
04HumanRandomized controlled trialEfficacy outcome
In people with HIV and NAFLD, tesamorelin decreased plasma CCL4 versus placebo.
In plain wordsIn people with HIV and fatty liver disease, tesamorelin lowered blood CCL4 compared with placebo.
Peptide
Tesamorelin
Outcome
DecreaseCCL4
Study
n = 61
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Circulating concentrations of 13 proteins were significantly decreased, and no proteins increased, by tesamorelin.
2 context sentences(design, population, supporting numbers)
Summary · context
These included 4 chemokines (CCL3, CCL4, CCL13 [MCP4], IL8 [CXCL8]), 2 cytokines (IL-10 and CSF-1), and 4 T-cell associated molecules (CD8A, CRTAM, GZMA, ADGRG1), as well as ARG1, Gal-9, and HGF.
Summary · context
92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.
Report a problemFND-3385272004
05HumanRandomized controlled trialEfficacy outcome
In people with HIV and NAFLD, tesamorelin decreased plasma CCL13 (MCP4) versus placebo.
In plain wordsIn people with HIV and fatty liver disease, tesamorelin lowered blood CCL13 compared with placebo.
Peptide
Tesamorelin
Outcome
DecreaseCCL13 (MCP4)
Study
n = 61
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Circulating concentrations of 13 proteins were significantly decreased, and no proteins increased, by tesamorelin.
2 context sentences(design, population, supporting numbers)
Summary · context
These included 4 chemokines (CCL3, CCL4, CCL13 [MCP4], IL8 [CXCL8]), 2 cytokines (IL-10 and CSF-1), and 4 T-cell associated molecules (CD8A, CRTAM, GZMA, ADGRG1), as well as ARG1, Gal-9, and HGF.
Summary · context
92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.
Report a problemFND-3385272005
06HumanRandomized controlled trialEfficacy outcome
In people with HIV and NAFLD, tesamorelin decreased plasma IL8 (CXCL8) versus placebo.
In plain wordsIn people with HIV and fatty liver disease, tesamorelin lowered blood IL8 compared with placebo.
Peptide
Tesamorelin
Outcome
DecreaseIL8 (CXCL8)
Study
n = 61
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Circulating concentrations of 13 proteins were significantly decreased, and no proteins increased, by tesamorelin.
2 context sentences(design, population, supporting numbers)
Summary · context
These included 4 chemokines (CCL3, CCL4, CCL13 [MCP4], IL8 [CXCL8]), 2 cytokines (IL-10 and CSF-1), and 4 T-cell associated molecules (CD8A, CRTAM, GZMA, ADGRG1), as well as ARG1, Gal-9, and HGF.
Summary · context
92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.
Report a problemFND-3385272006
07HumanRandomized controlled trialEfficacy outcome
In people with HIV and NAFLD, tesamorelin decreased plasma IL-10 versus placebo.
In plain wordsIn people with HIV and fatty liver disease, tesamorelin lowered blood IL-10 compared with placebo.
Peptide
Tesamorelin
Outcome
DecreaseIL-10
Study
n = 61
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Circulating concentrations of 13 proteins were significantly decreased, and no proteins increased, by tesamorelin.
2 context sentences(design, population, supporting numbers)
Summary · context
These included 4 chemokines (CCL3, CCL4, CCL13 [MCP4], IL8 [CXCL8]), 2 cytokines (IL-10 and CSF-1), and 4 T-cell associated molecules (CD8A, CRTAM, GZMA, ADGRG1), as well as ARG1, Gal-9, and HGF.
Summary · context
92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.
Report a problemFND-3385272007
08HumanRandomized controlled trialEfficacy outcome
In people with HIV and NAFLD, tesamorelin decreased plasma CSF-1 versus placebo.
In plain wordsIn people with HIV and fatty liver disease, tesamorelin lowered blood CSF-1 compared with placebo.
Peptide
Tesamorelin
Outcome
DecreaseCSF-1
Study
n = 61
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Circulating concentrations of 13 proteins were significantly decreased, and no proteins increased, by tesamorelin.
2 context sentences(design, population, supporting numbers)
Summary · context
These included 4 chemokines (CCL3, CCL4, CCL13 [MCP4], IL8 [CXCL8]), 2 cytokines (IL-10 and CSF-1), and 4 T-cell associated molecules (CD8A, CRTAM, GZMA, ADGRG1), as well as ARG1, Gal-9, and HGF.
Summary · context
92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.
Report a problemFND-3385272008
09HumanRandomized controlled trialEfficacy outcome
In people with HIV and NAFLD, tesamorelin decreased plasma CD8A versus placebo.
In plain wordsIn people with HIV and fatty liver disease, tesamorelin lowered blood CD8A compared with placebo.
Peptide
Tesamorelin
Outcome
DecreaseCD8A
Study
n = 61
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Circulating concentrations of 13 proteins were significantly decreased, and no proteins increased, by tesamorelin.
2 context sentences(design, population, supporting numbers)
Summary · context
These included 4 chemokines (CCL3, CCL4, CCL13 [MCP4], IL8 [CXCL8]), 2 cytokines (IL-10 and CSF-1), and 4 T-cell associated molecules (CD8A, CRTAM, GZMA, ADGRG1), as well as ARG1, Gal-9, and HGF.
Summary · context
92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.
Report a problemFND-3385272009
10HumanRandomized controlled trialEfficacy outcome
In people with HIV and NAFLD, tesamorelin decreased plasma CRTAM versus placebo.
In plain wordsIn people with HIV and fatty liver disease, tesamorelin lowered blood CRTAM compared with placebo.
Peptide
Tesamorelin
Outcome
DecreaseCRTAM
Study
n = 61
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Circulating concentrations of 13 proteins were significantly decreased, and no proteins increased, by tesamorelin.
2 context sentences(design, population, supporting numbers)
Summary · context
These included 4 chemokines (CCL3, CCL4, CCL13 [MCP4], IL8 [CXCL8]), 2 cytokines (IL-10 and CSF-1), and 4 T-cell associated molecules (CD8A, CRTAM, GZMA, ADGRG1), as well as ARG1, Gal-9, and HGF.
Summary · context
92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.
Report a problemFND-3385272010
11HumanRandomized controlled trialEfficacy outcome
In people with HIV and NAFLD, tesamorelin decreased plasma GZMA versus placebo.
In plain wordsIn people with HIV and fatty liver disease, tesamorelin lowered blood GZMA compared with placebo.
Peptide
Tesamorelin
Outcome
DecreaseGZMA
Study
n = 61
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Circulating concentrations of 13 proteins were significantly decreased, and no proteins increased, by tesamorelin.
2 context sentences(design, population, supporting numbers)
Summary · context
These included 4 chemokines (CCL3, CCL4, CCL13 [MCP4], IL8 [CXCL8]), 2 cytokines (IL-10 and CSF-1), and 4 T-cell associated molecules (CD8A, CRTAM, GZMA, ADGRG1), as well as ARG1, Gal-9, and HGF.
Summary · context
92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.
Report a problemFND-3385272011
12HumanRandomized controlled trialEfficacy outcome
In people with HIV and NAFLD, tesamorelin decreased plasma ADGRG1 versus placebo.
In plain wordsIn people with HIV and fatty liver disease, tesamorelin lowered blood ADGRG1 compared with placebo.
Peptide
Tesamorelin
Outcome
DecreaseADGRG1
Study
n = 61
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Circulating concentrations of 13 proteins were significantly decreased, and no proteins increased, by tesamorelin.
2 context sentences(design, population, supporting numbers)
Summary · context
These included 4 chemokines (CCL3, CCL4, CCL13 [MCP4], IL8 [CXCL8]), 2 cytokines (IL-10 and CSF-1), and 4 T-cell associated molecules (CD8A, CRTAM, GZMA, ADGRG1), as well as ARG1, Gal-9, and HGF.
Summary · context
92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.
Report a problemFND-3385272012
13HumanRandomized controlled trialEfficacy outcome
In people with HIV and NAFLD, tesamorelin decreased plasma ARG1 versus placebo.
In plain wordsIn people with HIV and fatty liver disease, tesamorelin lowered blood ARG1 compared with placebo.
Peptide
Tesamorelin
Outcome
DecreaseARG1
Study
n = 61
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Circulating concentrations of 13 proteins were significantly decreased, and no proteins increased, by tesamorelin.
2 context sentences(design, population, supporting numbers)
Summary · context
These included 4 chemokines (CCL3, CCL4, CCL13 [MCP4], IL8 [CXCL8]), 2 cytokines (IL-10 and CSF-1), and 4 T-cell associated molecules (CD8A, CRTAM, GZMA, ADGRG1), as well as ARG1, Gal-9, and HGF.
Summary · context
92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.
Report a problemFND-3385272013
14HumanRandomized controlled trialEfficacy outcome
In people with HIV and NAFLD, tesamorelin decreased plasma Gal-9 versus placebo.
In plain wordsIn people with HIV and fatty liver disease, tesamorelin lowered blood Gal-9 compared with placebo.
Peptide
Tesamorelin
Outcome
DecreaseGal-9
Study
n = 61
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Circulating concentrations of 13 proteins were significantly decreased, and no proteins increased, by tesamorelin.
2 context sentences(design, population, supporting numbers)
Summary · context
These included 4 chemokines (CCL3, CCL4, CCL13 [MCP4], IL8 [CXCL8]), 2 cytokines (IL-10 and CSF-1), and 4 T-cell associated molecules (CD8A, CRTAM, GZMA, ADGRG1), as well as ARG1, Gal-9, and HGF.
Summary · context
92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.
Report a problemFND-3385272014
15HumanRandomized controlled trialEfficacy outcome
In people with HIV and NAFLD, tesamorelin decreased plasma HGF versus placebo.
In plain wordsIn people with HIV and fatty liver disease, tesamorelin lowered blood HGF compared with placebo.
Peptide
Tesamorelin
Outcome
DecreaseHGF
Study
n = 61
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Circulating concentrations of 13 proteins were significantly decreased, and no proteins increased, by tesamorelin.
2 context sentences(design, population, supporting numbers)
Summary · context
These included 4 chemokines (CCL3, CCL4, CCL13 [MCP4], IL8 [CXCL8]), 2 cytokines (IL-10 and CSF-1), and 4 T-cell associated molecules (CD8A, CRTAM, GZMA, ADGRG1), as well as ARG1, Gal-9, and HGF.
Summary · context
92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.
Report a problemFND-3385272015
16HumanRandomized controlled trialMechanism
In people with HIV and NAFLD, network analysis of the tesamorelin-reduced proteins suggested down-regulation of a closely related cluster of immune pathways.
In plain wordsIn people with HIV and fatty liver disease, a computer analysis suggested tesamorelin turned down a related group of immune pathways.
Peptide
Tesamorelin
Outcome
DecreaseImmune pathway network analysis
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Network analysis indicated close interaction among the gene pathways responsible for these proteins, with imputational analyses suggesting down-regulation of a closely related cluster of immune pathways.
1 context sentence(design, population, supporting numbers)
Summary · context
92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.
Report a problemFND-3385272016
17HumanRandomized controlled trialMechanism
In liver biopsies from people with HIV and NAFLD, targeted transcriptomics confirmed down-regulated immune activation pathways with tesamorelin.
In plain wordsIn liver samples from people with HIV and fatty liver disease, tesamorelin was linked to lower activity of immune pathways.
Peptide
Tesamorelin
Outcome
DecreaseHepatic immune pathway gene expression
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Targeted transcriptomics using liver tissue confirmed a significant end-organ signal of down-regulated immune activation pathways.
1 context sentence(design, population, supporting numbers)
Summary · context
92 biomarkers associated with immunity, chemotaxis, and metabolism were measured in plasma samples from 61 PWH with NAFLD who participated in a double-blind, randomized trial of tesamorelin versus placebo for 12 months.
Report a problemFND-3385272017

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableResults postedNCT02196831

Tesamorelin Effects on Liver Fat and Histology in HIV

Massachusetts General Hospitaln = 611 Jul 2015 to 24 Jul 2019

Human Immunodeficiency Virus (HIV) · Nonalcoholic Fatty Liver Disease (NAFLD) · Nonalcoholic Steatohepatitis (NASH)

Trial page ClinicalTrials.govUpdated 27 Jan 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.